These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
449 related articles for article (PubMed ID: 35674870)
21. Gut microenvironmental changes as a potential trigger in Parkinson's disease through the gut-brain axis. Chen SJ; Lin CH J Biomed Sci; 2022 Jul; 29(1):54. PubMed ID: 35897024 [TBL] [Abstract][Full Text] [Related]
22. l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements? Del-Bel E; Bortolanza M; Dos-Santos-Pereira M; Bariotto K; Raisman-Vozari R Synapse; 2016 Dec; 70(12):479-500. PubMed ID: 27618286 [TBL] [Abstract][Full Text] [Related]
23. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration. Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665 [TBL] [Abstract][Full Text] [Related]
24. Neuroinflammation in Parkinson's disease: role in neurodegeneration and tissue repair. Vivekanantham S; Shah S; Dewji R; Dewji A; Khatri C; Ologunde R Int J Neurosci; 2015; 125(10):717-25. PubMed ID: 25364880 [TBL] [Abstract][Full Text] [Related]
25. Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease. Gelders G; Baekelandt V; Van der Perren A J Immunol Res; 2018; 2018():4784268. PubMed ID: 29850629 [TBL] [Abstract][Full Text] [Related]
26. The mechanisms of white matter injury and immune system crosstalk in promoting the progression of Parkinson's disease: a narrative review. Ma W; Geng Y; Liu Y; Pan H; Wang Q; Zhang Y; Wang L Front Aging Neurosci; 2024; 16():1345918. PubMed ID: 38863783 [TBL] [Abstract][Full Text] [Related]
27. Current perspective of mitochondrial biology in Parkinson's disease. Ammal Kaidery N; Thomas B Neurochem Int; 2018 Jul; 117():91-113. PubMed ID: 29550604 [TBL] [Abstract][Full Text] [Related]
28. Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson's Disease. Caputi V; Giron MC Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29882798 [TBL] [Abstract][Full Text] [Related]
29. Oral ingestion of the environmental toxicant trichloroethylene in rats induces alterations in the gut microbiome: Relevance to idiopathic Parkinson's disease. Ilieva NM; Wallen ZD; De Miranda BR Toxicol Appl Pharmacol; 2022 Sep; 451():116176. PubMed ID: 35914559 [TBL] [Abstract][Full Text] [Related]
30. Mitigating neuroinflammation in Parkinson's disease: Exploring the role of proinflammatory cytokines and the potential of phytochemicals as natural therapeutics. Sharma P; Kishore A; De I; Negi S; Kumar G; Bhardwaj S; Singh M Neurochem Int; 2023 Nov; 170():105604. PubMed ID: 37683836 [TBL] [Abstract][Full Text] [Related]
31. Neuroinflammation: A Distal Consequence of Periodontitis. Li X; Kiprowska M; Kansara T; Kansara P; Li P J Dent Res; 2022 Nov; 101(12):1441-1449. PubMed ID: 35708472 [TBL] [Abstract][Full Text] [Related]
32. The role of inflammation in sporadic and familial Parkinson's disease. Deleidi M; Gasser T Cell Mol Life Sci; 2013 Nov; 70(22):4259-73. PubMed ID: 23665870 [TBL] [Abstract][Full Text] [Related]
33. Unravelling the role of gut microbiota in Parkinson's disease progression: Pathogenic and therapeutic implications. Rani L; Mondal AC Neurosci Res; 2021 Jul; 168():100-112. PubMed ID: 33417973 [TBL] [Abstract][Full Text] [Related]
34. [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease]. Hattori N Rinsho Shinkeigaku; 2004; 44(4-5):241-62. PubMed ID: 15287506 [TBL] [Abstract][Full Text] [Related]
35. Footprints of a microbial toxin from the gut microbiome to mesencephalic mitochondria. Esteves AR; Munoz-Pinto MF; Nunes-Costa D; Candeias E; Silva DF; Magalhães JD; Pereira-Santos AR; Ferreira IL; Alarico S; Tiago I; Empadinhas N; Cardoso SM Gut; 2023 Jan; 72(1):73-89. PubMed ID: 34836918 [TBL] [Abstract][Full Text] [Related]
36. Neuroinflammatory Responses and Parkinson' Disease: Pathogenic Mechanisms and Therapeutic Targets. Yang L; Mao K; Yu H; Chen J J Neuroimmune Pharmacol; 2020 Dec; 15(4):830-837. PubMed ID: 32529463 [TBL] [Abstract][Full Text] [Related]
37. Dysbiosis of gut microbiota and microbial metabolites in Parkinson's Disease. Sun MF; Shen YQ Ageing Res Rev; 2018 Aug; 45():53-61. PubMed ID: 29705121 [TBL] [Abstract][Full Text] [Related]
38. Glycosphingolipids and neuroinflammation in Parkinson's disease. Belarbi K; Cuvelier E; Bonte MA; Desplanque M; Gressier B; Devos D; Chartier-Harlin MC Mol Neurodegener; 2020 Oct; 15(1):59. PubMed ID: 33069254 [TBL] [Abstract][Full Text] [Related]
39. Potential treatment of Parkinson's disease with omega-3 polyunsaturated fatty acids. Li P; Song C Nutr Neurosci; 2022 Jan; 25(1):180-191. PubMed ID: 32124682 [TBL] [Abstract][Full Text] [Related]
40. Mitochondrial Dysfunction, Protein Misfolding and Neuroinflammation in Parkinson's Disease: Roads to Biomarker Discovery. Picca A; Guerra F; Calvani R; Romano R; Coelho-Júnior HJ; Bucci C; Marzetti E Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680141 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]